Showing 801-810 of 1371 results for "".
Caring for the Transgender Patient
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/caring-for-the-transgender-patient/23410/Dr. Doris Day offers pearls on dermatologic care for transgender patients.Treating Psoriasis in 2015
https://practicaldermatology.com/topics/psoriasis/treating-psoriasis-in-2015/21212/An expert panel of dermatologists gathered at the Maui Derm for Dermatologists 2015 meeting to discuss everything from new therapies and comorbidities to genetic issues related to psoriasis.Dermatology Recruitment in the Age of Private Equity
https://practicaldermatology.com/issues/september-2025/dermatology-recruitment-in-the-age-of-private-equity/37638/A recruiting executive offers a balanced view from the fieldDerm Residency 2.0; AADA Legislative Conference; Call for Cases
https://practicaldermatology.com/youngmd-connect/resident-resource-center/derm-residency-20-aada-legislative-conference-call-for-cases/20949/Weighing the Prospects of Biosimilars
https://practicaldermatology.com/columns/clinical-focus-1/weighing-the-prospects-of-biosimilars/21477/If they are found to be comparable to the “originators,” biosimilar agents may offer patients significant therapeutic benefits as well as cost efficiency.A Highly Effective Topical Compounded Medication for the Treatment of Cutaneous Warts
https://practicaldermatology.com/topics/general-topics/a-highly-effective-topical-compounded-medication-for-the-treatment-of-cutaneous-warts/20583/A compounded formulation with an adhesive vehicle shows promise for one of the most common and frustrating conditions to treat in dermatology.What Do New PhRMA Guidelines Mean for Dermatology?
https://practicaldermatology.com/topics/general-topics/PD0309_04-php/22858/Revisions to the "Code on Interactions" are taking effect, but what do they really mean for the typical clinician?DermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approveConsidering Liver Health in Psoriasis: New Assessment Options
https://practicaldermatology.com/topics/psoriasis/considering-liver-health-in-psoriasis-new-assessment-options/23429/A rapid, non-invasive liver exam addresses growing need for early identification and monitoring of liver disease among patients with psoriasis.Top 10 Ways to Improve Acne Treatment
https://practicaldermatology.com/topics/practice-management/top-10-ways-to-improve-acne-treatment/21151/Tips for enhancing treatment regimens for better results.